Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.51 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.51 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.51 |
| ▸ | GAPDH | P04406 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.51 |
| ▸ | STAT6 | P42226 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioinosine SCHEMBL18314189 | 1.00 | ALDH1A1 (0.66) | ALDH1A1LMNATDP1PDE4APDE4B | |
| Adenosine SCHEMBL29840889 | 0.86 | ADORA2A (0.52) | ALDH1A1LMNATDP1MEN1KMT2A | |
| Inosine SCHEMBL1682742 | 0.85 | PAX8 (0.57) | ALDH1A1LMNATDP1MEN1KMT2A | |
| Inosine SCHEMBL20138538 | 0.85 | PAX8 (0.57) | ALDH1A1LMNATDP1MEN1KMT2A | |
| Inosine SCHEMBL15903470 | 0.85 | PAX8 (0.57) | ALDH1A1LMNATDP1MEN1KMT2A | |
| Inosine SCHEMBL568027 | 0.85 | PAX8 (0.57) | ALDH1A1LMNATDP1MEN1KMT2A | |
| Inosine SCHEMBL7633338 | 0.85 | PAX8 (0.57) | ALDH1A1LMNATDP1MEN1KMT2A | |
| Thioinosine Monophosphate SCHEMBL24059906 | 0.82 | TAS1R3 (0.57) | PDE4APDE4BPDE4CPDE4DADORA1 | |
| Thioinosine Monophosphate SCHEMBL5690866 | 0.82 | TAS1R3 (0.57) | PDE4APDE4BPDE4CPDE4DADORA1 | |
| Thioinosine Monophosphate SCHEMBL20266286 | 0.82 | TAS1R3 (0.57) | PDE4APDE4BPDE4CPDE4DADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366650-A1 | TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-07 | — | — | US | claimed |
| CN-116773710-A | Kit for covering metabolome and metabolic flow of multiple metabolites and use method | 清华大学 | 2023-09-19 | — | — | CN | claimed |
| CN-113624862-B | Metabolome covering multiple metabolites, metabolic flux analysis method and kit | 清华大学 | 2023-04-07 | — | — | CN | claimed |
| EP-3682888-B1 | MERCAPTOPURINE RIBONUCLEOSIDE ANALOGUES FOR ALTERING TELOMERASE MEDIATED TELOMERE | UNIV TEXAS (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20240366650-A1 | TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-07 | — | — | US | disclosed |
| US-12070472-B2 | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-08-27 | — | — | US | disclosed |
| CN-117946075-A | Cyclin K degrading agent | 杭州阿诺生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946076-A | Cyclin K degrading agent | 杭州阿诺生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117946088-A | Cyclin K degrading agent | 杭州阿诺生物医药科技有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-117377764-A | Multivalent oligonucleotide reagents and methods of use thereof | 中美瑞康核酸技术(南通)研究院有限公司 | 2024-01-09 | — | — | CN | disclosed |
| CN-111918863-B | Heterocyclic compounds | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| EP-3728282-B1 | 2'3' CYCLIC DINUCLEOTIDES WITH PHOSPHONATE BOND ACTIVATING THE STING ADAPTOR PROTEIN | INST OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR V V I (CZ) | 2023-11-22 | — | — | EP | disclosed |
| CN-116848099-A | Cyclin K degrading agent | 杭州阿诺生物医药科技有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116773710-A | Kit for covering metabolome and metabolic flow of multiple metabolites and use method | 清华大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-116113406-A | GAS41 inhibitors and methods of use thereof | 密歇根大学董事会 | 2023-05-12 | — | — | CN | disclosed |
| CN-108699110-B | Integrin binding peptides and uses thereof | 特温特大学 | 2023-04-28 | — | — | CN | disclosed |
| WO-2023025225-A1 | CYCLIN K DEGRADATION AGENT | 杭州阿诺生物医药科技有限公司 | 2023-03-02 | — | — | WO | disclosed |
| WO-2023023871-A1 | COMBINATION OF AN IGE MONOCLONAL ANTIBODY SPECIFIC TO A CANCER ANTIGEN AND NK CELL FOR THE TREATMENT OF CANCER | CANARIABIO INC. (KR) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023021319-A1 | MONOCLONAL ANTIBODIES AGAINST HER2/NEU AND USES THEREOF | ONCOQUEST PHARMACEUTICALS INC. (KR) | 2023-02-23 | — | — | WO | disclosed |
| CN-109640987-B | Bridged bicyclic inhibitors of MENIN-MLL and methods of use | 库拉肿瘤学公司 | 2022-12-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366650-A1 | TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS | TERT, POT1, TERF2 | ALDH1A1 2008/4885LMNA 769/4885TDP1 14/4885 |
| US-12070472-B2 | Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds | TERT, POT1, TERF2 | ALDH1A1 2008/4885LMNA 769/4885TDP1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.